Drug Profile
Research programme: nucleic acid therapeutics - Takeda/Wave Life Sciences
Alternative Names: Nucleic acid therapies - Takeda/Wave Life Sciences; Stereopure oligonucleotidesLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda; WaVe life Sciences
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Nucleic acids; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 31 Dec 2023 Wave Life Sciences terminates its collaboration with Takeda with respect to C9 Target and ATXN3 Target
- 02 Feb 2022 Pharmacodynamics data from a preclinical studies in CNS disorders released by WaVe life Sciences
- 18 Oct 2021 Wave Life Sciences and Takeda Pharmaceutical Company terminated its research and development agreement for nucleic acid therapies for CNS disorders